In this study, we analyzed for the first time whether ACADL and MCM2 immunostainings, used as surrogates to determine molecular groups MG3 and MG4, could predict the recurrence risk of atypical meningiomas and to identify cases which could benefit from adjuvant treatments in clinical practice. Here, MCM2 is linked to meningioma.